P2Y₁₂inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials

Figures

• 

  Fig 1. Primary outcome of MACCE. Cumulative incidences were calculated using Kaplan-Meier method and compared with log-rank test. (Top panel) One stage analysis accounting for differences in baseline hazard and treatment effects across trials. Mixed effects models were used to calculate hazard ratios and 95% CIs and multivariable mixed effects models to calculate adjusted hazard ratios and 95% CIs (sensitivity analysis). The corresponding P values were derived from Wald type testing. (Bottom panel) Two stage analysis by random effects models with inverse variance weighting. CI=confidence interval; ASCET=ASpirin non-responsiveness and Clopidogrel clinical Endpoint Trial; CAPRIE=Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events; GLASSY=GLOBAL LEADERS Adjudication Sub-Study; HOST-EXAM=Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy; MACCE=major adverse cardiac and cerebrovascular events (composite of cardiovascular death, myocardial infarction, or stroke); STOPDAPT-2=ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

• 

  Fig 2. Co-primary outcome of major bleeding. Cumulative incidences were calculated using Kaplan-Meier method and compared with log-rank test. (Top panel) One stage analysis accounting for differences in baseline hazard and treatment effects across trials. Mixed effects models were used to calculate hazard ratios and 95% CIs and multivariable mixed effects models to calculate adjusted hazard ratios and 95% CIs (sensitivity analysis). The corresponding P values were derived from Wald type testing. (Bottom panel) Two stage analysis by random effects models with inverse variance weighting. ASCET=ASpirin non-responsiveness and Clopidogrel clinical Endpoint Trial; CAPRIE=Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events; CI=confidence interval; GLASSY=GLOBAL LEADERS Adjudication Sub-Study; HOST-EXAM=Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy; STOPDAPT-2=ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

• 

  Fig 3. Key secondary outcome of NACCE. Cumulative incidences were calculated using Kaplan-Meier method and compared with log-rank test. (Top panel) One stage analysis accounting for differences in baseline hazard and treatment effects across trials. Mixed effects models were used to calculate hazard ratios and 95% CIs and multivariable mixed effects models to calculate adjusted hazard ratios and 95% CIs (sensitivity analysis). The corresponding P values were derived from Wald type testing. (Bottom panel) Two stage analysis by random effects models with inverse variance weighting. ASCET=ASpirin non-responsiveness and Clopidogrel clinical Endpoint Trial; CAPRIE=Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events; CI=confidence interval; GLASSY=GLOBAL LEADERS Adjudication Sub-Study; HOST-EXAM=Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy; NACCE=net adverse cardiac and cerebrovascular events (composite of cardiovascular death, myocardial infarction, stroke, or major bleeding); STOPDAPT-2=ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

• 

  Fig 4. Cardiovascular death. Cumulative incidences were calculated using the Kaplan-Meier method and compared with log-rank test. Multivariable mixed effects models were used to calculate adjusted hazard ratios and 95% CIs in sensitivity analysis. The corresponding P values were derived from Wald type testing. (Bottom panel) Two stage analysis by random effects models with inverse variance weighting. ASCET=ASpirin non-responsiveness and Clopidogrel clinical Endpoint Trial; CAPRIE=Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events; CI=confidence interval; GLASSY=GLOBAL LEADERS Adjudication Sub-Study; HOST-EXAM=Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy; MACCE=major adverse cardiac and cerebrovascular events (composite of cardiovascular death, myocardial infarction, or stroke); STOPDAPT-2=ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

• 

  Fig 5. Myocardial infarction. Cumulative incidences were calculated using the Kaplan-Meier method and compared with log-rank test. Multivariable mixed effects models were used to calculate adjusted hazard ratios and 95% CIs in sensitivity analysis. The corresponding P values were derived from Wald type testing. (Bottom panel) Two stage analysis by random effects models with inverse variance weighting. ASCET=ASpirin non-responsiveness and Clopidogrel clinical Endpoint Trial; CAPRIE=Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events; CI=confidence interval; GLASSY=GLOBAL LEADERS Adjudication Sub-Study; HOST-EXAM=Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy; MACCE=major adverse cardiac and cerebrovascular events (composite of cardiovascular death, myocardial infarction, or stroke); STOPDAPT-2=ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

• 

  Fig 6. Stroke. Cumulative incidences were calculated using the Kaplan-Meier method and compared with log-rank test. Multivariable mixed effects models were used to calculate adjusted hazard ratios and 95% CIs in sensitivity analysis. The corresponding P values were derived from Wald type testing. (Bottom panel) Two stage analysis by random effects models with inverse variance weighting. ASCET=ASpirin non-responsiveness and Clopidogrel clinical Endpoint Trial; CAPRIE=Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events; CI=confidence interval; GLASSY=GLOBAL LEADERS Adjudication Sub-Study; HOST-EXAM=Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy; MACCE=major adverse cardiac and cerebrovascular events (composite of cardiovascular death, myocardial infarction, or stroke); STOPDAPT-2=ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

• 

  Fig 7. Subgroup analysis for MACCE. Mixed effects models were used to calculate hazard ratios and 95% CIs (one stage analysis).Corresponding P values were derived from Wald type testing. BMI=body mass index; CI=confidence interval; MACCE=major adverse cardiac and cerebrovascular events; PRECISE-DAPT=PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy

• 

  Fig 8. Subgroup analysis for major bleeding. Prespecified subgroups were explored in terms of the co-primary outcome of major bleeding. Mixed effects models were used to calculate hazard ratios and 95% CIs (one stage analysis). The corresponding P values were derived from Wald type testing. BMI=body mass index; CI=confidence interval; PRECISE-DAPT=PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy